QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia
- Author
- OZEKI, Yuji1 2 ; FUJII, Kumiko1 ; KURIMOTO, Naoki3 ; YAMADA, Naoto3 ; OKAWA, Masako4 ; AOKI, Takesuke5 ; TAKAHASHI, Jun5 ; ISHIDA, Nobuya6 ; HORIE, Minoru7 ; KUNUGI, Hiroshi2
[1] Department of Psychiatry, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu, 321-0293, Japan
[2] Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashimachi, Kodaira, Tokyo, 187-8502, Japan
[3] Department of Psychiatry, Shiga University of Medical Science, Setatsukinowacyo, Otsu, 520-2121, Japan
[4] Department of Sleep Medicine, Shiga University of Medical Science, Setatsukinowacyo, Otsu, 520-2121, Japan
[5] Minakuchi Hospital, 2-2-43, Minakuchihonnmachi, Kouka, 528-0031, Japan
[6] Biwako Hospital, 1-8-5, Sakamoto, Otsu, 520-0113, Japan
[7] Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Setatsukinowacyo, Otsu, 520-2121, Japan - Source
Progress in neuro-psychopharmacology & biological psychiatry. 2010, Vol 34, Num 2, pp 401-405, 5 p ; ref : 3/4 p
- CODEN
- PNPPD7
- ISSN
- 0278-5846
- Scientific domain
- Cognition; Neurology; Pharmacology drugs; Psychology, psychopathology, psychiatry
- Publisher
- Elsevier, Amsterdam
- Publication country
- Netherlands
- Document type
- Article
- Language
- English
- Author keyword
- Antipsychotics QT prolongation Schizophrenia Sudden death
- Keyword (fr)
- Antipsychotique Arrêt cardiocirculatoire Chlorpromazine Halopéridol Homme Hypnotique Lévomépromazine Mort subite Neuroleptique Olanzapine Pharmacothérapie QT long Quétiapine Rispéridone Schizophrénie Sultopride Toxicité Zotépine Antagoniste dopamine Antagoniste sérotonine Benzisoxazole dérivé Cardiopathie Dérivé de la benzamide Dérivé de la butyrophénone Dérivé de la dibenzodiazépine Dérivé de la dibenzothiazépine Dérivé de la dibenzothiépine Dérivé de la phénothiazine Dérivé de la thiénobenzodiazépine Pathologie de l'appareil circulatoire Récepteur sérotoninergique Récepteur α1-adrénergique Traitement
- Keyword (en)
- Antipsychotic Cardiocirculatory arrest Chlorpromazine Haloperidol Human Hypnotic Levomepromazine Sudden death Neuroleptic Olanzapine Pharmacotherapy Prolonged QT interval Quetiapine Risperidone Schizophrenia Sultopride Toxicity Zotepine Dopamine antagonist Serotonin antagonist Benzisoxazole derivatives Heart disease Benzamide derivatives Butyrophenone derivatives Dibenzodiazepine derivatives Dibenzothiazepine derivatives Dibenzothiepin derivatives Phenothiazine derivatives Thienobenzodiazepine derivatives Cardiovascular disease Serotonine receptor α1-Adrenergic receptor Treatment
- Keyword (es)
- Antipsicótico Paro cardiocirculatorio Clorpromazina Haloperidol Hombre Hipnótico Levomepromazina Muerte súbita Neuroléptico Olanzapina Farmacoterapia QT largo Quetiapina Risperidona Esquizofrenia Sultoprida Toxicidad Zotepina Antagonista dopamina Antagonista serotonina Benzisoxazol derivado Cardiopatía Benzamida derivado Butirofenona derivado Dibenzodiazepina derivado Dibenzotiazepina derivado Dibenzothiepina derivado Fenotiazina derivado Tienobenzodiazepina derivado Aparato circulatorio patología Receptor serotoninérgico Receptor α1-adrenérgico Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B03 Psycholeptics: tranquillizer, neuroleptic.
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment / 002B02U03 Toxicity: cardiovascular system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12A Heart / 002B12A02 Cardiac dysrhythmias
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B18 Psychopathology. Psychiatry / 002B18C Adult and adolescent clinical studies / 002B18C06 Psychoses / 002B18C06A Schizophrenia
- Francis
- 770 Psychology. Psychoanalysis. Psychiatry / 770-D Psychopathology. Psychiatry / 770-D03 Adult and adolescent clinical studies / 770-D03F Psychoses / 770-D03F01 Schizophrenia
- Francis
- 770 Psychology. Psychoanalysis. Psychiatry / 770-E Psychopharmacology / 770-E03 Psycholeptics: tranquillizer, neuroleptic…
- Discipline
- Cardiology. Circulatory system Drugs toxicity and drug intoxications Pharmacological treatments Psychopathology. Psychiatry. Clinical psychology Toxicology
- Origin
- Inist-CNRS
- Database
- FRANCIS ; PASCAL
- INIST identifier
- 22514611
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.pnpbp.2010.01.008 
https://dx.doi.org/10.1016/j.pnpbp.2010.01.008
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:27:\"10.1016\/j.pnpbp.2010.01.008\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:9:\"\u0000*\u0000jtitle\";s:60:\"Progress in neuro-psychopharmacology & biological psychiatry\";s:9:\"\u0000*\u0000stitle\";s:44:\"Prog. neuro-psychopharmacol. biol. psychiatr\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"401\";s:8:\"\u0000*\u0000epage\";s:3:\"405\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0278-5846\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"OZEKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:13:\"FUJII, Kumiko\";i:1;s:15:\"KURIMOTO, Naoki\";i:2;s:13:\"YAMADA, Naoto\";i:3;s:13:\"OKAWA, Masako\";i:4;s:14:\"AOKI, Takesuke\";i:5;s:14:\"TAKAHASHI, Jun\";i:6;s:14:\"ISHIDA, Nobuya\";i:7;s:13:\"HORIE, Minoru\";i:8;s:15:\"KUNUGI, Hiroshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PNPPD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:27:\"10.1016\/j.pnpbp.2010.01.008\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:9:\"\u0000*\u0000jtitle\";s:60:\"Progress in neuro-psychopharmacology & biological psychiatry\";s:9:\"\u0000*\u0000stitle\";s:44:\"Prog. neuro-psychopharmacol. biol. psychiatr\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"401\";s:8:\"\u0000*\u0000epage\";s:3:\"405\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0278-5846\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"OZEKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:13:\"FUJII, Kumiko\";i:1;s:15:\"KURIMOTO, Naoki\";i:2;s:13:\"YAMADA, Naoto\";i:3;s:13:\"OKAWA, Masako\";i:4;s:14:\"AOKI, Takesuke\";i:5;s:14:\"TAKAHASHI, Jun\";i:6;s:14:\"ISHIDA, Nobuya\";i:7;s:13:\"HORIE, Minoru\";i:8;s:15:\"KUNUGI, Hiroshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PNPPD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:27:\"10.1016\/j.pnpbp.2010.01.008\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:27:\"10.1016\/j.pnpbp.2010.01.008\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:9:\"\u0000*\u0000jtitle\";s:60:\"Progress in neuro-psychopharmacology & biological psychiatry\";s:9:\"\u0000*\u0000stitle\";s:44:\"Prog. neuro-psychopharmacol. biol. psychiatr\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"401\";s:8:\"\u0000*\u0000epage\";s:3:\"405\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0278-5846\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"OZEKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:13:\"FUJII, Kumiko\";i:1;s:15:\"KURIMOTO, Naoki\";i:2;s:13:\"YAMADA, Naoto\";i:3;s:13:\"OKAWA, Masako\";i:4;s:14:\"AOKI, Takesuke\";i:5;s:14:\"TAKAHASHI, Jun\";i:6;s:14:\"ISHIDA, Nobuya\";i:7;s:13:\"HORIE, Minoru\";i:8;s:15:\"KUNUGI, Hiroshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PNPPD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:27:\"10.1016\/j.pnpbp.2010.01.008\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:9:\"\u0000*\u0000jtitle\";s:60:\"Progress in neuro-psychopharmacology & biological psychiatry\";s:9:\"\u0000*\u0000stitle\";s:44:\"Prog. neuro-psychopharmacol. biol. psychiatr\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"401\";s:8:\"\u0000*\u0000epage\";s:3:\"405\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0278-5846\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"OZEKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:13:\"FUJII, Kumiko\";i:1;s:15:\"KURIMOTO, Naoki\";i:2;s:13:\"YAMADA, Naoto\";i:3;s:13:\"OKAWA, Masako\";i:4;s:14:\"AOKI, Takesuke\";i:5;s:14:\"TAKAHASHI, Jun\";i:6;s:14:\"ISHIDA, Nobuya\";i:7;s:13:\"HORIE, Minoru\";i:8;s:15:\"KUNUGI, Hiroshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PNPPD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:27:\"10.1016\/j.pnpbp.2010.01.008\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:9:\"\u0000*\u0000jtitle\";s:60:\"Progress in neuro-psychopharmacology & biological psychiatry\";s:9:\"\u0000*\u0000stitle\";s:44:\"Prog. neuro-psychopharmacol. biol. psychiatr\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"401\";s:8:\"\u0000*\u0000epage\";s:3:\"405\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0278-5846\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"OZEKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:13:\"FUJII, Kumiko\";i:1;s:15:\"KURIMOTO, Naoki\";i:2;s:13:\"YAMADA, Naoto\";i:3;s:13:\"OKAWA, Masako\";i:4;s:14:\"AOKI, Takesuke\";i:5;s:14:\"TAKAHASHI, Jun\";i:6;s:14:\"ISHIDA, Nobuya\";i:7;s:13:\"HORIE, Minoru\";i:8;s:15:\"KUNUGI, Hiroshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PNPPD7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
